Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current opinion: the OCEANIC trial journey: from failure to breakthrough?

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Antidotes for Anticoagulation Reversal.

The New England journal of medicine·2026
Same author

Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.

Research and practice in thrombosis and haemostasis·2026
Same author

Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort.

Thrombosis research·2026
Same author

Thrombin generation and the pharmacodynamics of parenteral anticoagulants.

Pharmacological reviews·2026
Same author

Andexanet alfa for the reversal of anticoagulation: Dutch practice data.

Research and practice in thrombosis and haemostasis·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

InforMatrix: ADP antagonists in acute coronary syndromes.

Robert Janknegt1, Lex Ruiters, Hugo Ten Cate

  • 1Orbis Medisch Centrum , P.O. Box 5500, 6130 MB Sittard-Geleen , the Netherlands. r.janknegt@orbisconcern.nl

Expert Opinion on Pharmacotherapy
|January 7, 2012
PubMed
Summary
This summary is machine-generated.

InforMatrix provides a rational framework for selecting pharmacotherapies, comparing ADP antagonists like clopidogrel, prasugrel, and ticagrelor based on efficacy, safety, and cost. It aids formulary decisions by quantifying drug property importance.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Related Experiment Videos

Last Updated: May 26, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Area of Science:

  • Pharmacology
  • Health Economics
  • Clinical Decision Support

Background:

  • InforMatrix is an interactive model supporting rational pharmacotherapeutic strategy selection through transparent methodologies.
  • It facilitates evidence-based drug choice by evaluating multiple criteria.

Purpose of the Study:

  • To apply the InforMatrix model to compare key adenosine diphosphate (ADP) antagonists.
  • To evaluate clopidogrel, prasugrel, and ticagrelor using defined selection criteria for acute coronary syndrome treatment.

Main Methods:

  • InforMatrix was utilized to compare clopidogrel, prasugrel, and ticagrelor.
  • Selection criteria included efficacy, safety, tolerability, ease of use, applicability, and cost.
  • Comparative studies, including placebo-controlled and double-blind trials, informed the assessment.

Main Results:

  • The comparison highlighted differences in efficacy, safety, and acquisition costs among ADP antagonists.
  • Generic clopidogrel presents a significant cost advantage where available.
  • Potential efficacy benefits of prasugrel and ticagrelor require balancing against clopidogrel's extensive clinical data.

Conclusions:

  • InforMatrix quantifies differences in drug properties and user-assigned importance, fostering rational formulary decision-making.
  • The model supports discussions on the relative merits of clopidogrel, prasugrel, and ticagrelor, particularly regarding efficacy and cost.
  • It aids in navigating the complexities of drug selection for acute coronary syndromes.